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Background: Despite the laparoscopic approach becoming the standard in colorectal surgery, postoperative pain
management for minimally invasive surgery is still mainly based on strategies that have been established for open
surgical procedures. Patient-controlled epidural and intravenous analgesia are considered standard postoperative
analgesia regimens in colorectal surgery. Epidural analgesia provides excellent analgesia, but is increasingly scrutinized
in laparoscopic surgery since postoperative pain after the laparoscopic approach is significantly reduced. Moreover,
epidural analgesia can be associated with numerous complications. Therefore, epidural analgesia is no longer
recommended for the management of postoperative pain in laparoscopic colorectal surgery. Likewise, patient-controlled
intravenous analgesia is subject to significant side effects. Given these important limitations of the traditional strategies for
postoperative analgesia, effective and efficient alternatives in patients undergoing laparoscopic colorectal surgery are
needed. Both the transversus abdominis plane block and systemically administered lidocaine have already been reported
to effectively reduce pain after laparoscopic colorectal surgery. We hypothesize that the transversus abdominis plane block
is superior to perioperative intravenous lidocaine.
Methods/design: One hundred and twenty five patients undergoing laparoscopic colorectal surgery will be included in
this prospective, randomized, double-blind controlled clinical trial. Patients will be randomly allocated to three different
postoperative strategies: postoperative patient-controlled intravenous analgesia with morphine (control group, n = 25), a
transversus abdominis plane block with ropivacaine 0.375% at the end of surgery plus postoperative patient-controlled
intravenous analgesia with morphine (TAP group, n = 50), or perioperative intravenous lidocaine plus postoperative
patient-controlled intravenous analgesia with morphine (LIDO group, n = 50). As the primary outcome parameter, we will
evaluate the opioid consumption during the first 24 postoperative hours. Secondary endpoints include the Numeric
Rating Scale, time to return of intestinal function, time to mobilization, inflammatory response, incidence of postoperative
nausea and vomiting, length of hospital stay and postoperative morbidity as assessed with the Clavien-Dindo
classification.
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Discussion: Recognizing the importance of a multimodal approach for perioperative pain management, we aim to
investigate whether a transversus abdominis plane block delivers superior pain control in comparison to perioperative
intravenous lidocaine and patient-controlled intravenous analgesia with morphine alone.
Trial registration: EudraCT Identifier: 2014-001499-73; 31 July 2014.
Keywords: Colorectal surgery, Postoperative painBackground
A laparoscopic approach is now considered the gold
standard in colorectal resection for benign and malig-
nant disease [1]. Laparoscopic surgery is associated with
a significant reduction in postoperative pain and opioid
consumption, lower morbidity, faster recovery and shorter
hospital stay [1]. However, strategies for postoperative pain
management after laparoscopic surgery are mainly derived
from concepts that have been established for open surgical
procedures [2]. As such, patient-controlled epidural and
intravenous analgesia are still the most frequently used
techniques for postoperative analgesia after laparoscopic
colorectal surgery [3]. Epidural analgesia (EA) is known to
provide excellent pain control; however, the role of EA
in laparoscopic surgery is increasingly being scrutinized
[1]. Following laparoscopic colorectal surgery, the use
of EA has been shown to result in a prolonged time to
mobilization, an increase in hospital costs, length of hos-
pital stay and a higher incidence of urinary tract infections
[1,4] EA can also be associated with disastrous complica-
tions including epidural hematoma or abscess [5]. An add-
itional problem is that central neuraxial anesthesia cannot
be applied in patients with chronic anticoagulant therapy
or those suffering from coagulopathies.
Modern multimodal analgesia concepts have been
demonstrated to provide postoperative analgesia as
equally as effective as EA in patients undergoing laparo-
scopic colorectal surgery [3,6]. Therefore, recently pub-
lished guidelines from the UK do no longer recommend
EA as standard therapy for pain control after laparo-
scopic colorectal surgery [1,7].
The majority of multimodal analgesia concepts rely on
the systemic administration of opioids under the control
of the patient (patient-controlled intravenous analgesia
(PCIA)). Unfortunately, PCIA with morphine is frequently
limited by important side effects including sedation, con-
stipation, itching, postoperative nausea and vomiting
(PONV), and respiratory depression [8].
There is a quest for effective and efficient alternatives
for postoperative analgesia in patients undergoing laparo-
scopic colorectal surgery.
The transversus abdominis plane (TAP) block is a rela-
tively new regional anesthesia technique that provides
analgesia of the parietal peritoneum, the anterior abdom-
inal wall, and the skin [9]. Performed under ultrasoundguidance, the block has been demonstrated to be simple
and safe. [9] Furthermore, the use of TAP blocks results in
a reduced cumulative opioid consumption in the first 24
postoperative hours [10].
In the last years, the use of systemic lidocaine as a
co-analgesic has gained increasing interest for the treat-
ment of acute postoperative pain. Lidocaine is a local
anesthetic amide with analgesic, antihyperalgesic and
anti-inflammatory properties [11]. Published data on
the efficacy of the systemic administration of lidocaine
perioperatively are inconsistent [11]. In abdominal sur-
gery, lidocaine has been demonstrated to result in lower
postoperative pain scores, a significantly reduced use of
anesthetics and of postoperative analgesics [12,13].
While both the TAP block and systemically adminis-
tered lidocaine have been reported to effectively reduce
pain after laparoscopic colorectal surgery, no random-
ized data comparing the role of TAP block versus sys-
temic lidocaine are available [10,14-16].
Given the fact that the TAP block is a potent locore-
gional anesthesia technique, we hypothesize that, in pa-
tients undergoing laparoscopic colorectal surgery, TAP
block provides superior postoperative analgesia when
compared to perioperative intravenous lidocaine.Methods/design
Study design
This study is a single-center, prospective, randomized,
double-blind, controlled trial. The study will be performed
in accordance with the Declaration of Helsinki and has
been approved by the ethics committee of the University
Hospitals of the KU Leuven on 31 July 2014 with the
reference number ML10699. The trial is registered under
EudraCT 2014-001499-73. Figure 1 provides an overview
of the trial design.Population
All consecutive patients scheduled for elective laparo-
scopic resection and candidates for enhanced recovery
after surgery will be included in the study after informed
consent has been obtained. Patients will be recruited in
the Department of Abdominal Surgery of the University
Hospitals of the KU Leuven.
Patients for laparoscopic colorectal surgery
Pre-operative assessment of eligibility
Exclusion Criteria
1.
participate
Patient’s refusal to
2. Allergy for local 
anaesthetics
3. Chronic opioid use
4. Liver dysfunction
5. Renal insuffiency
6. Epilepsy
7. Psychomotoric retardation
8. BMI>40
9. Sleep apnea
10. Cardiac rhythm disorders
Inclusion Criteria
1. Age between 18-75 years
2. Elective laparoscopic 
colorectal surgery
3. ASA I - III
Obtainment of written 
informed consent
Baseline assessment
Randomization
(after induction of anesthesia)
Surgical procedure
PCIA TAP block Systemic lidocaine
Primary outcome parameter:
Cumulative morphine consumption during 
the first 24 postoperative hours
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Secondary endpoints:
1) Postoperative NRS-scores (day 0-3)
2) Time to first analgesia
3) Time to return of intestinal function
(defined as the time to first flatus and the 
time to the First post-operative intake of
solid food)
4) time to first mobilization
5) Incidence of post-operative nausea and
vomiting during the first 24 hours
6) Length of stay on the PACU and in the 
hospital
7) Postoperative morbidity as quantified by 
the Clavien-Dindo classification
8) Perioperative inflammatory response 
Figure 1 Trial design chart. ASA, American Society of Anaesthesiologists; NRS, numeric rating scale; PACU, postoperative anesthesia care unit;
PCIA, patient-controlled intravenous analgesia; TAP, transversus abdominis plane.
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Patients will be randomized to one of three groups that
will either receive a TAP block with ropivacaine 0.375%
at the end of surgery plus postoperative PCIA with mor-
phine (TAP group, n = 50), perioperative intravenous
lidocaine plus postoperative PCIA with morphine (LIDO
group, n = 50), or only postoperative PCIA with mor-
phine (control group, n = 25). The patients will be ran-
domized to one of the study groups using a computer
generated list. Allocation concealment will be ensured
by enclosing assignments in sealed, opaque, sequentially
numbered envelopes which will be opened only upon
arrival of the patient in the operation room [17].
Postoperative outcomes will be assessed by research
personnel that remain blinded to the type of interven-
tion throughout the study.
Inclusion and exclusion criteria
The inclusion criteria are: (1) aged between 18 and 75 years,
(2) elective laparoscopic colorectal surgery, (3) American
Society of Anesthesiologists risk classification < IV.
The exclusion criteria include: (1) refusal of the
patient, (2) known hypersensitivity to study medications,
(3) chronic opioid use, (4) liver insufficiency (defined as
a serum bilirubin ≥2 mg/dl), (5) renal insufficiency (de-
fined by estimated glomerular filtration rate ≤60 ml/min/
1.73 m2), (6) epilepsy, (7) psychomotoric retardation, (8)
morbid obesity (defined as a body mass index >40), (9)
obstructive sleep apnea syndrome, (10) cardiac rhythm
disorders.
Intervention plan
In all patients, the Enhanced Recovery After Surgery proto-
col will be used in order to standardize perioperative treat-
ment in all groups [18]. The Enhanced Recovery After
Surgery protocol comprises: (1) no preoperative bowel
preparation, (2) avoidance of prolonged fasting, (3) no pre-
medication, (4) intraoperative administration of PONV and
antibiotic prophylaxis, (5) maintenance of normothermia,
(6) restrictive fluid management, (7) early postoperative re-
moval of the gastric tube and the bladder catheter, (8) early
oral nutrition, and (9) early mobilization of the patient.
Induction and maintenance of anesthesia
After preoxygenation, anesthesia will be induced with a
bolus injection of propofol (2 mg/kg) and an intravenous
infusion of remifentanil (target-controlled infusion with a
calculated plasma level of 4 to 5 ng/ml). Tracheal intub-
ation will be facilitated with cis-atracurium (0.15 mg/kg).
General anesthesia will be maintained by inhalation of
sevoflurane. In all groups, sevoflurane end-tidal concen-
trations will be titrated according to the instantaneously
registered electroencephalography monitor in order to
achieve a bispectral index value between 40 and 60.PONV prophylaxis will be achieved with intravenous
dexamethasone (0.1 mg/kg) at induction and intraven-
ous ondansetron (0.1 mg/kg) 30 minutes before the end
of surgery.
In all patients, standard American Society of Anesthesi-
ologists monitoring will be applied, including electrocar-
diogram, pulse oximetry, capnography, and temperature
measurements. In addition, patients will be monitored
using bispectral index, invasive arterial and central venous
pressure measurements, and relaxometry.
Interventional treatment
TAP group At the end of surgery, a bilateral single shot
TAP block will be performed under ultrasound guidance.
At each side, 20 ml ropivacaine 0.375% and clonidine
0.5 μg/kg will be injected into the “triangle of Petit”,
which is located between the internal oblique muscle
and the transverse abdominal muscle.
LIDO group A bolus of 1.5 mg/kg of intravenous lido-
caine will be administered after induction of anesthesia,
followed by a continuous infusion of intravenous lido-
caine at 1.5 mg/kg per hour. The lidocaine infusion will
be stopped 4 hours after arrival in the postoperative
anesthesia care unit (PACU).
To achieve blinding of the patients and study observers,
patients in the TAP group and in the control group will
perioperatively receive a placebo infusion with saline at a
comparable rate as the lidocaine infusion in the LIDO
group. Moreover, in patients of both the LIDO group and
the control group, adhesive tapes will be attached at the
level of the assumed TAP block puncture site.
Postoperative analgesia
Irrespective of group allocation, all patients will receive a
combination of intravenous analgesics 30 minutes before
the end of the surgery: paracetamol 15 mg/kg, ketorolac
0.5 mg/kg (maximum 30 mg), 0.2 mg/kg morphine.
Moreover, each patient will receive PCIA with mor-
phine. The PCIA pump will be programmed in an
on-demand-only mode without a basal rate, allowing for
a bolus injection of 1.5 mg every 7 minutes with a max-
imum of 30 mg every 4 hours. The PCIA pump will be
stopped on the third postoperative day.
Once the PCIA pump is discontinued, piritramide
0.5 mg/kg and paracetamol 15 mg/kg will be offered upon
request.
PONV will be treated with intravenous droperidol
0.625 mg (in the PACU) or intravenous ondansetron
4 mg (on the ward).
Postoperative care unit
The patients will be transferred to the PACU for con-
tinuous monitoring of vital signs. The Aldrete score will
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assessed at rest and during coughing by a numeric rating
scale (0 = no pain, 10 = the worst imaginable pain). As
soon as the numeric rating scale score exceeds 3, pa-
tients will be treated with 1 mg intravenous morphine
until freedom from pain is achieved. Severity of pain will
be monitored every 15 minutes during the first 2 hours
of the PACU stay and hourly during the remaining
PACU stay. Patients will stay at least 4 hours in the
PACU. Patients will be discharged from the PACU only
once the Aldrete score is 9, and once there is no
evidence of pain and/or PONV.
Follow-up visits
Patients will be visited once daily throughout their hos-
pital stay by research personnel.
Primary endpoint
As the primary outcome parameter, we will evaluate the
cumulative morphine consumption in the first 24 post-
operative hours.
Secondary endpoints
Secondary outcome parameters include: (1) numeric
rating scale; (2) time to return of intestinal function
(defined as the time to first flatus and the time to the
first postoperative intake of solid food); (3) time to first
mobilization; (4) the incidence of PONV during the first
24 hours, (5) length of stay on the PACU and in the hos-
pital; (6) postoperative morbidity as quantified by the
Clavien-Dindo classification [18]; (7) perioperative inflam-
matory response (as measured by serial serum levels of
C-reactive protein, interleukin-6, and interleukin-10 - for
this, serum samples (5 ml each) will be obtained from the
arterial catheter or the central venous line: (1) after induc-
tion of anesthesia, (2) at the end of surgery, (3) 12 hours
after induction, (4) 24 hours after induction, (5) day 1, (6)
day 2 and (7) day 3.
Assessment of safety
The interventional treatment will be administered to
patients with standard hemodynamic monitoring in the
setting of a fully equipped operation theatre. This
enables immediate detection and treatment of adverse
events. Administration of study drugs will be immedi-
ately stopped in cases where the study participant shows
a relevant deterioration. Also, after leaving the operation
room, all patients will be closely monitored for the oc-
currence of eventual (severe) adverse events, first on the
PACU and later on the surgical ward. Moreover, the in-
clusion of each individual patient into the study is indi-
cated in the electronic hospital information system and,
hence, is visible to all physicians and nurses involved in
the care of the patient. This facilitates reporting of(severe) adverse events to the principal investigator. The
principal investigator will report suspected unexpected
serious adverse reactions to the federal health authorities.
Data analysis
All statistical analyses will be performed using SAS soft-
ware version 9.2 (SAS Inc., Cary, NC, USA). All tests
will be two-sided, and significance will be set at P < 0.05.
Two-sided t tests for the ratio of means will be used to
compare the opium consumption between the TAP and
LIDO and between the TAP and control group, respect-
ively; 95% confidence intervals for the ratio will be re-
ported. If the log-transformed data (natural logarithm)
show departure from normality (based on the Shapiro–
Wilk W-test statistic) a Mann–Whitney U-test will be
used to verify the robustness of the conclusion. Propor-
tions will be compared between groups with Fisher's
exact tests, and Mann–Whitney U-tests will be used to
compare the length of stay and the postoperative mor-
bidity classification.
Time-to-event outcomes will be measured from end of
surgery until the occurrence of the event. Patients will
be censored if they do not experience the event at the
time of the last follow-up. Of note, the number of cen-
sored events is expected to be negligible since the events
of interest (mobilization and return of intestinal func-
tion) are a prerequisite for a patient’s discharge from the
hospital. Kaplan-Meier estimates will be used to obtain
the cumulative distribution curves for the event times
and groups will be compared using the log-rank test. A
linear model for longitudinal measurements with an un-
structured covariance matrix will be used to evaluate the
evolution of the inflammatory response. An analysis will
be performed for each serum marker separately, after
applying a transformation of the response if needed to
obtain a symmetric distribution of the model residuals.
Completed case record forms will be reviewed by an
investigator or a study nurse for completeness and cor-
rectness before digitalization and statistical analysis. At
this time point, missing data will be identified and, if
possible, drawn from source data and filled into the case
record forms. Missing data not being found in the
source data is not expected as all clinical data (including
routine data) are mandatorily collected in the electronic
hospital information system and outcomes of all abdom-
inal surgical patients are routinely documented in detail
according to the standards of the British “Enhanced
Recovery Programme”. In any case, data will be analyzed
according to the intention-to-treat principle.
Sample size calculation
The study has been powered to detect the differences in
primary outcome between the TAP and the LIDO
group, and between the TAP and the control group.
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consumption was derived from reported standard devi-
ation or interquartile range values in the literature [10,19]
and found to be in the range 0.19 to 0.73. Further, in an
unpublished retrospective evaluation of 10 patients in our
institution, we observed a coefficient of variation of 0.35.
Hence, a coefficient of variation equal to 0.5 was assumed
in the power calculation. Using a two-sided test for a ratio
of means (with alpha = 5%), 44 patients per group are
needed to show a 25% reduction in the 24 hour morphine
consumption in the TAP versus LIDO group when a
power of 80% is to be achieved. The assumption that
perioperative lidocaine also yields a reduction of 25%
compared to PCIA alone (control group) implies a ratio of
0.752 = 0.5625 for TAP versus control. Recruiting 22
patients in the control group yields more than 99% power
to detect this difference, with 44 patients included in the
TAP group and using the same test. As such, 110 patients
in total are needed. To compensate for possible drop-outs,
we will include 125 patients in total. They will be random-
ized into the TAP group, the LIDO group and the PCIA
group with weights equal to 2, 2 and 1.
Note that to enable confirmatory claims about both
comparisons without inflating the type I error, a hier-
archical closed test procedure is used (that is, both com-
parisons are tested on a 5% level) with the comparison
of TAP versus control being tested only in case that the
comparison of TAP versus LIDO is significant.
Discussion
Benefits
Recently, both TAP block and perioperative intravenous
lidocaine have been shown to efficiently control postop-
erative pain in patients after laparoscopic colorectal sur-
gery. Both techniques have been demonstrated to reduce
postoperative opioid consumption, but no comparative
data are available. We hypothesize that the use of TAP
blocks will be superior for postoperative pain control
when compared with the perioperative administration of
intravenous lidocaine or PCIA. The TAP block has been
proven to be safe and is technically easy to perform, par-
ticularly under ultrasound guidance.
Possible benefits of the TAP block include its ease of
performance, proven effectiveness, the reduction of
postoperative opioid consumption, and the fact that it
can be performed even in patients under anticoagulant
therapy or with coagulopathies. Moreover, systemic side
effects as happens with patient-controlled EA and PCIA
are avoided.
Risks
Risks are mainly due to the systemic toxicity of local
anesthetics. The intravenous use of lidocaine may lead
to a close-related systemic toxicity that can affect thecentral nervous system (drowsiness, confusion, eu-
phoria, double vision, seizures) and the cardiovascular
system (hypotension, bradycardia, arrhythmias). How-
ever, the doses as suggested in our study have repeatedly
been demonstrated to be safe and to result in plasma
concentrations that are far below the level of toxicity
(5 μg/ml) [14]. As a safety measure, patients with im-
paired lidocaine metabolism due to liver dysfunction
are excluded from study participation. Moreover, pa-
tients are continuously monitored by electrocardiog-
raphy during the administration of lidocaine.
The use of ropivacaine for the TAP block may also
cause system toxicity. The incidence of systemic toxicity
of local anesthetics after peripheral nerve blocks is esti-
mated to be 1:1000, with mostly minor symptoms. Of
note, ropivacaine has an excellent safety profile with
only minor cardiac toxicity. Ropivacaine has therefore
become a popular choice for high-dose, high-volume
fascial plane blocks including the TAP block. Risk of
inadvertent intravenous, bowel or nerve injection will be
minimized by ultrasound guidance and needle aspiration
prior to injection [20].
According to the recent guidelines of the American
Society of Regional Anesthesia, patients will be continu-
ously monitored with electrocardiogram, blood pressure
measurement and pulse oximetry for at least 30 minutes
after injection of ropivacaine [21].
Trial status
Patient recruitment will start in September 2014. The
predicted study completion date is December 2015.
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